Compare ResMed Inc. (RMD) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.73B), while iShares 20 Plus Year Treasury Bond ETF trades at $81.46. The key difference: ResMed Inc. pays a 1.2% dividend while iShares 20 Plus Year Treasury Bond ETF pays none, and ResMed Inc. is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| RMD | TLT | |
|---|---|---|
Market Cap | $31.73B | — |
Sector | Health | — |
52-Week High | $283.28 | $92.06 |
52-Week Low | $182.82 | $81.35 |
Enterprise Value | $31.08B | — |
Dividend Yield | 1.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% on the day, with a bearish technical signal and key support at $218. The company reported strong Q4 2026 results, beating EPS estimates at $2.95, and maintains robust profitability with a 26.94% net income margin. Revenue growth remains solid, reaching $5.15B in 2025, though weak 2027 sales guidance has pressured the stock. A dividend of $0.66 is scheduled for payment in September 2026.
Outlook is mixed: strong fundamentals and a consensus price target of $235.70 suggest upside, but bearish technicals and investor lawsuits pose near-term risks. The stock offers value with a P/E of 21.19, yet competitive and regulatory challenges require monitoring for sustained growth.
TLT trades at $82.20, down slightly by 0.01% with a bearish technical signal from moving averages. The ETF faces headwinds from rising Treasury yields and potential large-scale selling by institutional investors like Norway's sovereign wealth fund. Recent Treasury buyback announcements of up to $6 billion in long-dated debt provide some support, but the overall trend remains challenging amid inflation concerns and rising oil prices.
The outlook for TLT remains cautious as rising interest rates and inflation pressures continue to weigh on long-duration bonds. While current RSI levels suggest potential oversold conditions, the fundamental environment of higher yields and potential institutional selling creates significant downside risk. Investors should monitor Treasury policy actions and global bond market developments closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
